ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this regard, dasatinib, a SFKs inhibitor, is effective when treating chronic myeloid leukemia patients with resistance or intolerance to imatinib, a BCR-ABL tyrosine kinase inhibitor [16].